Nonbullous congenital ichthyosiform erythroderma (NCIE) is a nonsyndromic form of autosomal recessive congenital ichthyosis characterized by hyperkeratosis and a disruption in the epidermal permeability barrier. Identification of mutations in two lipoxygenases (LOXs), ALOX12B (12R-LOX) and ALOXE3 (eLOX3), and further functional studies implicate ALOX12B and ALOXE3 in the etiology of NCIE. Here, we report a mutation in Alox12b in the recessive ethylnitrosurea-induced mouse mutant, mummy (Alox12b mmy-Bei ). mummy mutants have red, scaly skin and die perinatally. Histologically, mummy mutants display defects in the epidermis. We mapped mummy to a 1.9 Mb interval on Chr. 11 containing Alox12b (12R-LOX), Aloxe3 (eLOX3) and Alox15b (8-LOX). Sequencing of all three genes identified a nonsense mutation in the catalytic domain of Alox12b. We demonstrate that mummy mutants have a disrupted epidermal permeability barrier and that the nonsense mutation in mummy abolishes the enzyme activity of 12R-LOX. The mummy mutant provides a mouse model for LOX-mediated NCIE and is the first described mouse mutant affecting epidermal barrier formation identified by forward genetics.
INTRODUCTION
The epidermal permeability barrier is a specialized epidermal structure that protects the skin from dehydration and the entry of chemical or infectious agents and is essential for terrestrial life. Barrier function is provided by the stratum corneum, the outer layer of the epidermis composed of terminally differentiated keratin-filled cells with crosslinked cornified envelopes (CEs) sealed by lipid bilayers. Incomplete barrier function in humans is observed in premature infants, inflammatory skin diseases such as psoriasis, and in congenital ichthyoses (reviewed in Richard, 2004; Segre, 2006) .
Nonsyndromic autosomal recessive congenital ichthyosis (ARCI) is a genetically and clinically heterogeneous class of skin diseases marked by scaly skin and impaired epidermal barrier function. The most common clinical cases of ARCI are of two types: lamellar ichthyosis (LI) and nonbullous congenital ichthyosiform erythroderma (NCIE, CIE, or NBCIE) (reviewed in Akiyama et al., 2003) . The genetic basis of several ARCI loci have been identified, and mutations in some genes can result in multiple forms of ARCI (reviewed in Akiyama et al., 2003; Richard, 2004; Akiyama, 2006) . Many ARCI disease genes encode proteins involved in the synthesis of the CE or epidermal lipid metabolism, such as TGM1, a transglutaminase that crosslinks the CE; ABCA12, an ATPbinding cassette transporter involved in lipid trafficking, and ALOX12B and ALOXE3, two lipoxygenases (LOXs) involved in fatty acid metabolism.
In the mouse, several genes required for epidermal barrier function have been identified. These include CE and intercellular junction structural proteins, proteins involved in CE protein crosslinking and lipid synthesis, and transcription factors (reviewed in Segre, 2003 Segre, , 2006 . Two such genes are known human congenital ichthyoses disease genes: Tgm1 (autosomal recessive LI and NCIE) and loricrin (autosomal dominant NCIE) (reviewed in Richard, 2004) . Here, we describe the first mouse mutation in the 12R-LOX, Alox12b, which is mutated in some human NCIE-affected individuals.
RESULTS
The recessive mummy mutant was identified in an ethylnitrosurea mutagenesis screen for recessive neonatal developmental defects (Herron et al., 2002) . Affected mice are born with red, shiny skin that rapidly desiccates and appears scaly (Figure 1a and b). The mutation causes lethality within 24 hours of birth. Histological analysis of newborn epidermis demonstrates a thickened, compressed stratum corneum in the affected mice in contrast to the normal basket-weave corneum layers in unaffected littermates (Figure 1c and d) .
The initial map position of the mummy mutation was determined by genotyping 10 affected intercross progeny and two parentals with a fixed whole genome single nucleotide polymorphism (SNP) panel of 394 SNPs (Moran et al., 2006) . Retention of homozygous alleles for the mutagenized strain (A/J) and positive logarithm of odds (LOD) association at a single locus demonstrates linkage (LOD 2.81) to a 21 Mb interval on chromosome (Chr) 11 (rs4228770 (58.1 Mb) -rs13481117 (79.0 Mb) (Figure 2a) ). The genetic interval was further refined to 1.9 Mb (D11Mit115 (67.4 Mb) -D11Mit298 (69.3 Mb)) by genotyping recombinant affected mice and an additional 15 affected progeny with simple-sequence length polymorphism markers (data not shown). The refined 1.9 Mb genetic interval contains 41 RefSeq genes.
Three genes in the 1.9 Mb genetic interval, Alox12b, Aloxe3, and Alox15b, were evaluated for candidates for the mummy mutation based on several criteria. Firstly, these Alox genes comprise a family of epithelial-specific LOXs (hepoxylins) expressed in the mouse epidermis (Sun et al., 1998; Heidt et al., 2000) . Secondly, Alox15b (Alox8; 8-LOX) expression is upregulated in a mouse model of severe dermatitis (Schneider et al., 2004) . Thirdly, mutations in ALOX12B (12R-LOX) and ALOXE3 (eLOX3) have been identified in individuals with ARCI, specifically the ARCI subtype NCIE, an ichthyosis characterized by hyperkeratosis and a disruption of the epidermal permeability barrier (Jobard et al., 2002; Eckl et al., 2005) . Sequencing of all exons and intron-exon boundaries from all three genes was performed on genomic DNA from mummy-affected mutant mice.
We identified a G to A single base pair change in exon 14 of the Alox12b gene (Figure 2b ). The Alox12b gene encodes one transcript with 15 exons and a 701 amino-acid protein.
The mutation introduces a nonsense codon into the C-terminal LOX catalytic domain (W633X), which results in truncation of the protein by 68 amino acids. Mutated transcript is present in mummy homozygote skin, indicating the absence of nonsense-mediated mRNA decay (data not shown).
LOXs are lipid-peroxidizing enzymes that oxygenate polyunsaturated fatty acids to hydroperoxide derivatives (Samuelsson et al., 1987) . Mouse Alox12b protein (12R-LOX) oxygenates arachidonate methyl ester rather than arachidonic acid to 12R-hydroperoxyeicosatetraenoic acid (HETE) (Krieg et al., 1999) . To assess the affect of the mutation on the enzymatic activity of 12R-LOX, we overexpressed histidine (His)-tagged mutant W633X and wild-type Alox12b proteins in COS7 cells and assayed for 12R-LOX activity by incubating cell extracts with [ (a-b) mummy mutants are distinguishable from unaffected littermates at birth by their red skin that rapidly desiccates and appears scaly. (c-d) Newborn mummy dorsal skin shows a thickened stratum corneum by hematoxylin and eosin staining of sections (n ¼ 9 affected mice; n ¼ 10 unaffected mice, evaluated at E17.5, E18.5, and newborn). Bar ¼ 150 mm. Figure 2 . Genetic mapping and identification of the mummy mutation. (a) The mummy mutation was mapped to a 21 Mb interval on Chr 11 between SNPs rs4228770 (58.1 Mb) and rs13481117 (79.0 Mb) by performing a whole genome scan of 394 SNPs on two parental (A/J Â C57BL/6J) F1 and 10 affected F2 progeny. Alleles for the mutated A/J strain (M) are red; C57BL/6J background strain (B), blue; heterozygotes, yellow; and no calls, white. P for parental; U for unaffected and A for affected mice. Genotypes from two nonrecombinant simple-sequence length polymorphism markers, D11Mit29 (69.6 Mb) and D11Mit194 (73.2 Mb), are also shown. (b) Chromatograms of Alox12b genomic sequence in wild-type A/J (top) and mummy-affected (middle, bottom) mice showing a G to A mutation, which introduces a premature stop codon in mummy mutants.
performance liquid chromatography (HPLC) revealed that wild-type Alox12b converted the substrate to 12R-HETE and 12R-HETE methyl ester, whereas mutant Alox12b-W633X produced no detectable products (Figure 3 ). Expression levels of wild-type and mutant Alox12b proteins, as detected by Western blotting with an antibody against the His tag, were equivalent (data not shown). Thus, the mummy mutation W633X completely eliminates Alox12b enzymatic activity.
Identification of a loss-of-function mutation in mouse Alox12b, association of mutations in human ALOX12B in NCIE, and the neonatal mummy phenotype all suggest that epidermal permeability barrier function may be compromised in mummy mice. Formation of the permeability barrier is a highly patterned process that begins at E16 in the mouse and is completed by birth (Hardman et al., 1998) . Disruption of the skin barrier is lethal in mice, as demonstrated by the study of several perinatal lethal gene-targeted mutations affecting the skin barrier (reviewed in Segre, 2003; Leyvraz et al., 2005; Herrmann et al., 2005) . To test whether mummy mutants have a defective skin barrier, a dye permeability assay was performed on untreated E17.5 and E18.5 fetuses. X-gal substrate does not penetrate skin with a functional barrier and accessibility of X-gal to the skin produces a colored precipitate through endogenous b-galactosidase activity (Hardman et al., 1998) . mummy mutants do not show evidence of barrier acquisition as demonstrated by blue staining across the entire body at E17.5 and E18.5 (Figure 4a ).
An additional test of skin barrier function is to monitor mice for dehydration. E17.5 and E18.5 mice were dissected and revived, and weights were measured every hour for 6 h. mummy mutants lost between 21 and 27% of their body weight within 6 hours of birth indicating rapid dehydration, the likely cause of perinatal lethality (Figure 4b ).
DISCUSSION
Here we describe the first mouse mutation in the 12R-LOX, Alox12b, which was identified in an ethylnitrosurea mutagenesis screen for recessive perinatal developmental defects. In mummy (Alox12b mmy-Bei ) mice, a nonsense mutation in Alox12b leads to premature truncation of the protein and loss of LOX catalytic activity. Alox12b deficiency in mice leads to a lack of epidermal permeability barrier function and perinatal lethality. In humans, mutations in ALOX12B underlie the genetic basis for some cases of NCIE, one of the main clinical forms of ARCI. Like the mouse nonsense ]arachidonate methyl ester as substrate and the products analyzed by reversed-phase HPLC using a Waters Symmetry C18 column (25 Â 0.46 cm) with a solvent system of methanol/water/acetic acid (85:15:0.01, by volume) run at a flow rate of 1 ml/minute on an Agilent 2100 series HPLC system equipped with an on-line Flo-One Beta radioactive detector. Arachidonate methyl ester is used as the test substrate because mouse 12R-LOX does not metabolize free arachidonic acid (Krieg et al., 1999) . Top trace: profile of unlabeled standards added to the sample before injection and detected with UV recording at 235 nm. Middle trace: 
The weight of intercross progeny was measured every hour for the first 6 hours after birth. Dramatic weight loss of mummy homozygotes at E17.5 and E18.5 (n ¼ 5À/À), 21-27% weight loss compared with no more than 3% for control littermates
, shows a lack of barrier function.
www.jidonline.org 1895 mutation, all human point mutations tested result in abolishment or significant impairment of 12R-LOX activity (Eckl et al., 2005; Yu et al., 2005) .
The mummy mutant provides a mouse model for human NCIE, as mummy skin shares some of the features of NCIEaffected skin. NCIE-affected individuals display erythrodermic, scaly skin, an increase in stratum corneum thickness (hyperkeratosis), inflammation and impaired epidermal barrier function, with a range in phenotype severity (reviewed in Akiyama et al., 2003) . mummy mutants are born with shiny, red skin that rapidly desiccates because of a defective epidermal barrier. Histologically, the stratum corneum of late gestational and neonatal skin is thickened. Although NCIE is not typically lethal, mummy mice die within 24 hours of birth, presumably because of rapid dehydration. Thus, we are not able to observe the effects of Alox12b deficiency in the adult mouse. Lethality in mice and not humans has also been observed in transglutaminase-mediated barrier defects and ARCI, and may be owing to the lack of medical care for newborn mice or the larger surface area-to-volume ratio of mice compared with humans (Matsuki et al., 1998; Kuramoto et al., 2002; Segre 2006) .
Alox12b is a member of a family of epithelial-specific LOXs expressed in neonatal and adult mouse epidermis (Sun et al., 1998; Heidt et al., 2000) . Alox12b mRNA is first detected in the skin and other epithelial tissues at E15.5 and is highly expressed in newborn mouse epidermis (Sun et al., 1998 ). Alox12b's expression in late granular and squamous keratinocytes led to the proposal that Alox12b plays a role in skin barrier formation and terminal differentiation (Heidt et al., 2000) . The skin barrier begins to form at E16 when a precursor of the stratum corneum is first detected (Hardman et al., 1998) . We observed a defect in epidermal permeability barrier (EPB) formation in mummy mice at E17.5. Given the expression of Alox12b and both the barrier and stratum corneum defects in mummy mice, we speculate that Alox12b activity is required for terminal differentiation of keratinocytes and formation of a functional stratum corneum. To elucidate potentially a mechanism for the epidermal defects, examination of the morphology and integrity of CEs, lipid synthesis and processing, and ultrastructural cellular architecture will need to be performed.
The identification of several human ARCI disease genes, ALOX12B, ALOXE3, ichthyin, and FLJ39501, has led to the elucidation of an arachidonic acid metabolism LOX-dependent pathway in ARCI pathogenesis (Jobard et al., 2002; Yu et al., 2003; Lefevre et al., 2004; Lefevre et al., 2006) . It is still unclear whether the LOX-dependent pathway plays a structural or signaling role in epidermal differentation. The mouse mutant mummy provides a model that will facilitate further exploration of the role of LOXs in epidermal barrier formation and terminal differentiation of the skin.
MATERIALS AND METHODS

Histology
Newborn heads were fixed in Bouin's, embedded in paraffin, sectioned and stained with hematoxylin and eosin.
Genetic mapping
mummy was identified in an ethylnitrosurea mutagenesis screen for autosomal recessive developmental phenotypes (Herron et al., 2002) . The mutation was generated on the A/J strain and maintained by serial backcross to FVB/NJ. The mutation was outcrossed to C57BL/6J for mapping and phenotypic analysis. Ten affected F2-affected progeny and two F1 male parents were genotyped with a whole genome SNP panel containing 394 SNPs and simplesequence length polymorphisms (Moran et al., 2006) . Recombinant affected mice and an additional 15 affected mice were genotyped with simple-sequence length polymorphism markers to narrow the genetic interval to 1.9 Mb (D11Mit115 (67.4 Mb) -D11Mit298 (69.3 Mb); Genome Build 36).
DNA sequencing
High-throughput sequencing of exons and exon/intron boundaries of the Alox12b, Aloxe3, and Alox15b genes was performed as described previously (Moran et al., 2006) . Genomic DNA from the wild-type A/J strain and two mummy-affected mice were used as sequencing templates. Alox12b Vega Gene ID:OTTMUSG000000-005964 (www.ensembl.org/Mus_musculus).
Skin permeability assay E17.5-E18.5 untreated fetuses were stained with X-gal solution at low pH to assay endogenous epidermal b-galactosidase activity as described by Hardman et al. (1998) .
Wild-type and mutant Alox12b activity assay cDNA amplification and cloning. Total RNA was extracted from wild-type and mutant E18.5 skin with a Qiagen RNeasy Midi Kit (Qiagen, Valencia, CA). First strand cDNA was synthesized using Superscript III First Strand cDNA Synthesis Kit (oligo-dT primer; Invitrogen, Carlsbad, CA) and subsequently used as a template for polymerase chain reaction (PCR) amplification of wild-type Alox12b cDNA with Platinum Taq DNA Polymerase High Fidelity (Invitrogen) and cDNA-specific primers (forward primer 5 0 -GTGGTTCCCGCTG ACTGC-3 0 ; reverse primer 5 0 -TTACAGTGATTTTATTGGA-3 0 ). PCR product was cloned into pCR2.1TOPO and the cDNA sequence was verified by full-length sequencing. Wild-type and mutant cDNAs were cloned into the Gateway system for mammalian expression (Invitrogen). Briefly, the wild-type Alox12b cDNA pCR2.1TOPO clone was used as a template for PCR amplification of wild-type and mutant cDNA with Pfx50 DNA Polymerase (Invitrogen). PCR were performed with a common forward and distinct reverse primers; the mutant cDNA primer contained the point mutation (forward 5 0 -CACCATGGCCACCTA TAAAGTC-3 0 ; wild-type reverse primer 3 0 -CAGAAGGGTGGACTA GATGGA-3 0 ; mutant reverse primer 3 0 -GCTCCCGACAGAGAGTT CAG-3 0 ). Products were cloned into the pENTR/SD/D-TOPO vector using the pENTR Directional TOPO Cloning Kit (Invitrogen) according to manufacturer's protocol. After isolation of plasmid DNA with the Purelink HQ Mini Plasmid Kit (Invitrogen), wild-type and mutant Alox12b cDNAs were cloned into the Gateway destination vector pDEST26 (N-terminal fusion vector with in-frame 6 Â His-tag) by LR recombination using Gateway LR Clonase enzyme mix according to manufacturer's protocol.
